Effects of the thyroid hormone receptor agonist @entity30325 on metabolic rate and XXXX in @entity35 and primates: selective actions relative to 3,5,3'-triiodo-L-thyronine.

@entity28 @entity5434 @entity37629 @entity591 @entity2613 @entity4977 @entity30325 @entity35 @entity6145 @entity165
Current drug therapies for @entity28 are ineffective, and existing treatments for @entity4977 can be further improved. Thyroid hormones affect both conditions, although currently available nonselective thyromimetics are not clinically useful for such treatment due to cardiac side effects. Recent studies suggest that @entity6145 receptor subtype beta ( @entity37629 ) selective agonists have a profile in which @entity165 can be reduced with minimal @entity591 . The purpose of this study was to determine whether modest (5-10%) increases in metabolic rate could also be observed with minimal @entity591 after @entity37629 stimulation. For these studies, the @entity37629 selective agonist, @entity30325 , was used to assess selectivity for lipid-lowering and metabolic rate changes relative to @entity591 . Studies in @entity165 -fed @entity35 (7 d treatment) showed that @entity30325 reduced @entity165 ( @entity2613 (50) = 190 nmol/kg x d) approximately 30 times more potently than it induced @entity591 ( @entity2613 (15) = 5451 nmol/kg x d). T(3) showed no potency difference between @entity165 lowering and @entity591 . @entity30325 showed approximately 10-fold selectivity for increasing metabolic rate ( @entity2613 (5) = 477 nmol/kg x d) relative to @entity591 compared with T(3), which showed no selectivity. In @entity5434 treated for 7 d, significant @entity165 -lowering and lipoprotein (a) reduction was noted for both T(3) and @entity30325 , whereas no @entity591 was observed for @entity30325 , unlike T(3). T(3) and @entity30325 caused a significant (approximately 4%) reduction in body weight in these animals. Therefore, selective @entity37629 activation may be a potentially usefully treatment for @entity28 and reduction of low density lipoprotein @entity165 and reduction of the atherogenic risk factor lipoprotein (a).
